Ketamine for the Treatment of Depression in Parkinson's Disease
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to examine the efficacy, safety and mechanistic
underpinnings of a repeated dosing ketamine infusion paradigm compared to placebo in
individuals with PD.
A subset of participants in each arm will undergo baseline and post-treatment PET and fMRI
scans, to examine whether changes in synaptic density and reorganization of functional
networks underlie ketamine's putative antidepressant effects in PD.
Phase:
N/A
Details
Lead Sponsor:
Yale University
Collaborator:
Fox (Michael J.) Foundation for Parkinson's Research